coenzyme-q10 and Angina-Pectoris

The study included 1418 patients with FC I-IV stable angina of effort (42.4% men and 57.6% women, mean age 74.6 +/- 1.2 years). The possibility to supplement standard therapy with myocardial cytoprotectors (trimetasidin, mexidol, qudesan) was estimated in 4 groups of patients from the severity of pain syndrome, chronic cardiac insufficiency, and heart rhythm disturbances.

Topics: Aged; Angina Pectoris; Cytoprotection; Drug Therapy, Combination; Female; Humans; Male; Myocardium; Picolines; Trimetazidine; Ubiquinone

Topics: Angina Pectoris; Antioxidants; Cardiovascular Agents; Coenzymes; Cytoprotection; Female; Heart; Humans; Lipid Peroxidation; Male; Middle Aged; Myocardial Ischemia; Myocardium; Physical Exertion; Time Factors; Ubiquinone

The effects of oral treatment with coenzyme Q10 (120 mg/d) were compared for 28 days in 73 (intervention group A) and 71 (placebo group B) patients with acute myocardial infarction (AMI). After treatment, angina pectoris (9.5 vs. 28.1), total arrhythmias (9.5% vs. 25.3%), and poor left ventricular function (8.2% vs. 22.5%) were significantly (P < 0.05) reduced in the coenzyme Q group than placebo group. Total cardiac events, including cardiac deaths and nonfatal infarction, were also significantly reduced in the coenzyme Q10 group compared with the placebo group (15.0% vs. 30.9%, P < 0.02). The extent of cardiac disease, elevation in cardiac enzymes, and oxidative stress at entry to the study were comparable between the two groups. Lipid peroxides, diene conjugates, and malondialdehyde, which are indicators of oxidative stress, showed a greater reduction in the treatment group than in the placebo group. The antioxidants vitamin A, E, and C and beta-carotene, which were lower initially after AMI, increased more in the coenzyme Q10 group than in the placebo group. These findings suggest that coenzyme Q10 can provide rapid protective effects in patients with AMI if administered within 3 days of the onset of symptoms. More studies in a larger number of patients and long-term follow-up are needed to confirm our results.

Topics: Angina Pectoris; Antioxidants; Arrhythmias, Cardiac; Coenzymes; Double-Blind Method; Heart Ventricles; Humans; Male; Myocardial Infarction; Myocardium; Oxidative Stress; Placebos; Time Factors; Ubiquinone

The effects of coenzyme Q10(CoQ10) on exercise performance were studied in 12 patients, average age 56 years, with stable angina pectoris. The study involved a double-blind, placebo-controlled, randomized, crossover protocol, using multistage treadmill exercise tests. CoQ10(150 mg/day in 3 daily doses) was administered orally for 4 weeks, tended to reduce anginal frequency from 5.3 +/- 4.9 to 2.5 +/- 3.3 attacks for 2 weeks and nitroglycerin consumption from 2.6 +/- 2.8 to 1.3 +/- 1.7 tablets for 2 weeks compared with patients receiving the placebo, but the reduction was not statistically significant. Exercise time increased from 345 +/- 102 seconds with placebo to 406 +/- 114 seconds during CoQ10 treatment (p less than 0.05). The time until 1 mm of ST-segment depression occurred increased from 196 +/- 76 seconds with placebo to 284 +/- 104 seconds during CoQ10 treatment (p less than 0.01). During the exercise test, ST-segment depression, heart rate and pressure-rate product at the same and at the maximal workload showed no significant difference between patients after placebo and CoQ10 administration. The average CoQ10 plasma concentration increased from 0.95 +/- 0.48 microgram/ml to 2.20 +/- 0.98 microgram/ml after CoQ10 treatment. This increase was significantly related to the increase in exercise duration (r = 0.68, p less than 0.001). Only 1 patient had a loss of appetite, but continued therapy. This study suggests that CoQ10 is a safe and promising treatment for angina pectoris.

Topics: Aged; Angina Pectoris; Chronic Disease; Coenzymes; Double-Blind Method; Electrocardiography; Exercise Test; Female; Hemodynamics; Humans; Male; Middle Aged; Nitroglycerin; Random Allocation; Rest; Ubiquinone

Topics: Aged; Angina Pectoris; Coenzymes; Coronary Disease; Female; Heart Diseases; Humans; Male; Middle Aged; Ubiquinone; Urologic Diseases

Topics: Adult; Aged; Angina Pectoris; Coenzymes; Female; Humans; Injections, Intravenous; Male; Middle Aged; Physical Exertion; Ubiquinone